Literature DB >> 29436105

The association of nocturnal hypertension and nondipping blood pressure with treatment-resistant hypertension: The Jackson Heart Study.

Marguerite R Irvin1, John N Booth1, Mario Sims2, Adam P Bress3, Marwah Abdalla4, Daichi Shimbo4, David A Calhoun5, Paul Muntner1.   

Abstract

Apparent treatment-resistant hypertension (aTRH), nocturnal hypertension, and nondipping blood pressure (BP) have shared risk factors. The authors studied the association between aTRH and nocturnal hypertension and aTRH and nondipping BP among 524 black Jackson Heart Study participants treated for hypertension. Nocturnal hypertension was defined by mean nighttime systolic BP ≥120 mm Hg or diastolic BP ≥70 mm Hg. Nondipping BP was defined by mean nighttime to daytime systolic BP ratio >0.90. aTRH was defined by mean clinic systolic BP ≥140 mm Hg and/or diastolic BP ≥90 mm Hg with three medication classes or treatment with four or more classes. The risk for developing aTRH associated with nondipping BP and nocturnal hypertension was estimated. After multivariable adjustment, participants with aTRH were more likely to have nocturnal hypertension (prevalence ratio, 1.20; 95% confidence interval, 1.03-1.39) and nondipping (prevalence ratio, 1.25; 95% confidence interval, 1.09-1.43). Over a median 7.3 years of follow-up, nocturnal hypertension and nondipping BP at baseline were not associated with developing aTRH after adjustment. ©2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  Hypertension in blacks; ambulatory blood pressure/home blood pressure monitor; apparent treatment-resistant hypertension; nocturnal hypertension; nondipping blood pressure

Mesh:

Substances:

Year:  2018        PMID: 29436105      PMCID: PMC5907922          DOI: 10.1111/jch.13199

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  34 in total

1.  Sodium restriction shifts circadian rhythm of blood pressure from nondipper to dipper in essential hypertension.

Authors:  T Uzu; K Ishikawa; T Fujii; S Nakamura; T Inenaga; G Kimura
Journal:  Circulation       Date:  1997-09-16       Impact factor: 29.690

2.  European Society of Hypertension position paper on ambulatory blood pressure monitoring.

Authors:  Eoin O'Brien; Gianfranco Parati; George Stergiou; Roland Asmar; Laurie Beilin; Grzegorz Bilo; Denis Clement; Alejandro de la Sierra; Peter de Leeuw; Eamon Dolan; Robert Fagard; John Graves; Geoffrey A Head; Yutaka Imai; Kazuomi Kario; Empar Lurbe; Jean-Michel Mallion; Giuseppe Mancia; Thomas Mengden; Martin Myers; Gbenga Ogedegbe; Takayoshi Ohkubo; Stefano Omboni; Paolo Palatini; Josep Redon; Luis M Ruilope; Andrew Shennan; Jan A Staessen; Gert vanMontfrans; Paolo Verdecchia; Bernard Waeber; Jiguang Wang; Alberto Zanchetti; Yuqing Zhang
Journal:  J Hypertens       Date:  2013-09       Impact factor: 4.844

3.  Study design for genetic analysis in the Jackson Heart Study.

Authors:  James G Wilson; Charles N Rotimi; Lynette Ekunwe; Charmaine D M Royal; Mary E Crump; Sharon B Wyatt; Michael W Steffes; Adebowale Adeyemo; Jie Zhou; Herman A Taylor; Cashell Jaquish
Journal:  Ethn Dis       Date:  2005       Impact factor: 1.847

4.  Diurnal blood pressure pattern and development of prehypertension or hypertension in young adults: the CARDIA study.

Authors:  Anthony J Viera; Sha Zhu; Alan L Hinderliter; Daichi Shimbo; Sharina D Person; David R Jacobs
Journal:  J Am Soc Hypertens       Date:  2011-01-26

5.  Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008.

Authors:  Brent M Egan; Yumin Zhao; R Neal Axon; Walter A Brzezinski; Keith C Ferdinand
Journal:  Circulation       Date:  2011-08-08       Impact factor: 29.690

Review 6.  Ambulatory blood pressure phenotypes and the risk for hypertension.

Authors:  Anthony J Viera; Daichi Shimbo
Journal:  Curr Hypertens Rep       Date:  2014-10       Impact factor: 5.369

7.  Nocturnal reduction of blood pressure and the antihypertensive response to a diuretic or angiotensin converting enzyme inhibitor in obese hypertensive patients. TROPHY Study Group.

Authors:  M R Weir; E Reisin; B Falkner; H G Hutchinson; L Sha; M L Tuck
Journal:  Am J Hypertens       Date:  1998-08       Impact factor: 2.689

8.  Physical activity and cardiovascular disease in African Americans in Atherosclerosis Risk in Communities.

Authors:  Elizabeth J Bell; Pamela L Lutsey; Beverly G Windham; Aaron R Folsom
Journal:  Med Sci Sports Exerc       Date:  2013-05       Impact factor: 5.411

9.  Role of alpha-2 receptors in the regulation of renal function.

Authors:  J W Strandhoy
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

10.  STOP questionnaire: a tool to screen patients for obstructive sleep apnea.

Authors:  Frances Chung; Balaji Yegneswaran; Pu Liao; Sharon A Chung; Santhira Vairavanathan; Sazzadul Islam; Ali Khajehdehi; Colin M Shapiro
Journal:  Anesthesiology       Date:  2008-05       Impact factor: 7.892

View more
  4 in total

1.  The association of nocturnal hypertension and nondipping blood pressure with treatment-resistant hypertension: The Jackson Heart Study.

Authors:  Marguerite R Irvin; John N Booth; Mario Sims; Adam P Bress; Marwah Abdalla; Daichi Shimbo; David A Calhoun; Paul Muntner
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-02-13       Impact factor: 3.738

2.  Refractory hypertension focus on nighttime blood pressure and nondipping.

Authors:  Cesare Cuspidi; Marijana Tadic; Guido Grassi
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-02-13       Impact factor: 3.738

3.  Association of Obstructive Sleep Apnea With Nighttime Blood Pressure in African Americans: The Jackson Heart Study.

Authors:  Stephen Justin Thomas; Dayna A Johnson; Na Guo; Marwah Abdalla; John N Booth; Tanya M Spruill; Chandra L Jackson; Yuichiro Yano; Mario Sims; David Calhoun; Paul Muntner; Susan Redline
Journal:  Am J Hypertens       Date:  2020-10-21       Impact factor: 3.080

Review 4.  Resistant hypertension-defining the scope of the problem.

Authors:  Richard Chia; Ambarish Pandey; Wanpen Vongpatanasin
Journal:  Prog Cardiovasc Dis       Date:  2019-12-19       Impact factor: 11.278

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.